Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer

Cancer Investigation

Volumn 18, Issue 5, 2000, Pages 422-428

  Cohen, Roger B ^a   Mueller, Stacy C ^a   Haden, Kathy ^a   De Souza, Paul ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AFFECTIVE NEUROSIS; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; DYSGEUSIA; ESOPHAGUS CANCER; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; LUNG CANCER; MALE; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS;

EID: 0034121876     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009032813     Document Type: Article

References (34)

1. Canobbio L, Boccardo F, Pastorino G, et al.: Phase II study of Navelbine in advanced breast cancer. Semin Oncol 16(2 Suppl 4):33-36, 1989.
2. Romanini A, Surbone A, Ricci S, et al.: Phase II study of continuous infusion vinorelbine (CIV) in patients with locally pretreated advanced head and neck cancer. Proc AACR 34:205, 1993 (abstract 1222).
3. Le Chevalier T, Brisgand D, Douillard JY, et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994.
4. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667, 1979.
5. Binet S, Fellous A, Lataste H, et al.: In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16(2 Suppl 4):5-8, 1989.
6. McGuire WP, Rowinsky EK, Rosenshein NB, et al.: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989.
7. Fenelly D, Aghajanian C, Sharpiro F, et al.: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Oncol 15:187-192, 1997.
8. Breier S, Lebedinsky C, Pelayes L, et al.: Preliminary analysis, weekly paclitaxel. Proc ASCO 15:182, 1996 (abstract 382).
9. Alvarez A, Mickiewicz E, Piris N, et al.: Weekly taxol high dose intensity (DI) treatment. Phase II study. Proc ASCO 15:183, 1996 (abstract 383).
10. Seidman AD, Murphy B, Hudis C, et al.: Activity of taxol by weekly 1 hour infusion in patients with metastatic breast cancer: a phase II and pharmacologic study. Proc ASCO 16:148a, 1997 (abstract 517).
11. Chang A, Hui L, Boros L, et al.: Phase I study of weekly one-hour paclitaxel treatment in advanced malignant disease. Proc ASCO 16:16, 1997 (abstract 817).
12. Abu-Rustum N, Aghajanian C, Barakat R, et al.: Salvage weekly paclitaxel (Taxol) for recurrent ovarian cancer. Proc ASCO 16:364a, 1997 (abstract 1296).
13. Burriss HA, Fields S: Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Semin Oncol 21:14-20, 1994.
14. Weiselberg L, Budman D, O'Mara V, et al.: Phase I trial of sequential vinorelbine- paclitaxel in patients with metastatic breast cancer: early evidence of tolerability and efficacy. Proc ASCO 15:97, 1996 (abstract 54).
15. Chang AY, DeVore R, Johnson D: Pilot study of vinorelbine (Navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 23:19-21, 1996.
16. Tortoriello A, Facchini G, Caponigro F, et al.: Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 47:91-97, 1998.
17. Iaffaioli RV, Facchini G, Tortoriello A, et al.: Phase I study of vinorelbine and paclitaxel in small-cell lung cancer. Cancer Chemother Pharmacol 41:86-90, 1997.
18. Michelotti A, Gennari A, Salvadori B, et al.: Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study. Ann Oncol 7:857-860, 1996.
19. Parimoo D, Jeffers S, Muggia FM: Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst 88:1079-1080, 1996.
20. Budman D, Weiselberg L, O'Mara V: Severe neurotoxicity in vinorelbine-paclitaxel combinations. J Natl Cancer Inst 89:87-88, 1997.
21. Adams D: Synergy of vinorelbine-taxol combination treatment in two human breast cancer cell lines. Proc AACR 35:327, 1994 (abstract 1944).
22. Knick VC, Eberwein DJ, Miller CG: Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 87:1072-1107, 1995.
23. Budman DR, Calabro A, Stiel L, et al.: In vitro studies of paclitaxel in combination with either etoposide or vinorelbine: sequence dependent effects causing synergism or antagonism. Proc AACR 37: 1996 (abstract 2493).
24. Carles G, Braguer D, Sabeur G, et al.: The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cells. Anti-Cancer Drugs 9:209-221, 1998.
25. Photiou A, Shah P, Leong LK, et al.: In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines. Eur J Cancer 33:463-470, 1997.
26. de Souza PL, Myers CE: Synergy analysis of vinorelbine and paclitaxel in prostate cancer. Proc AACR 39:586, 1998 (abstract 3986).
27. Livingston RB, Ellis GK, Gralow JR, et al.: Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15:1395-1400, 1997.
28. Weber BL, Vogel C, Jones S, et al.: Intravenous vinorelbine as a first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730, 1995.
29. Twelves C, Dobbs N, Curnow A, et al.: A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 70:990-993, 1994.
30. Furuse K, Kubota K, Kawahara M, et al.: A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 11: 385-391, 1994.
31. Loeffler TM, Freund FW, Lipke J, et al.: Schedule and dose intensified paclitaxel (T) as weekly one hour infusion, evidence for an improved toxicity profile and response activity in pretreated solid tumors. Proc ASCO 14:470, 1995 (abstract 1522).
32. Akerly W, Glantz M, Choy H, et al.: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16:153-158, 1998.
33. Fety R, Vernillet L, Perrocheau G, et al.: Pharmacokinetic study of docetaxel (D) plus vinorelbine (V) combination as first line CT in patients with MBC. Proc AACR 37:183, 1996 (abstract 1250).
34. Miller CG, Knick VC, Eberwein D, et al.: Navelbine and paclitaxel combinations provide improved activity with reduced toxicity by an immune status dependent mechanisms. Proc AACR 37:437-438, 1996 (abstract 2989).